Bone density changes with enzyme therapy for Gaucher disease

Ehud Lebel, Altoon Dweck, A. Joseph Foldes, Yosef S. Golowa, Menachem Itzchaki, Ari Zimran, Deborah Elstein

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Gaucher disease is the most common lysosomal storage disease. Enzyme replacement therapy engenders improvement in hematological and visceral parameters; however, improvement in bone density (BMD) with treatment has not been confirmed. This study presents follow-up of BMD in the first tenpatients in Israel treated with low-dose recombinant enzyme for up to 108 months. BMD at femoral neck and lumbar spine was determined by dual-energy X-ray absorptiometry (DEXA) at the start of the trial, after 3-6 months, after 18-24 months, and at the most recent follow-up. BMD in all patients was very low at onset and never normalized. There was a decrease in BMD in all patients at 3-6 months. Older patients (four women, two men; >30 years of age) showed some improvement in BMD during treatment. Younger patients (four females; 18-23 years of age) did not show a statistically significant improvement. These findings might reflect the failure of patients with Gaucher disease to achieve expected peak bone density at appropriate chronological milestones despite treatment. None-theless, the z-scores of the older patients were better than those of the younger patients, implying some catch-up period. Yet, some patients with Gaucher disease evince rapid onset of osteoporosis in early adulthood. Enzyme treatment per se, as well as attendant improved well-being and increased physical activity, may induce amelioration in BMD at this later stage. One may consider adding anti-osteoporosis therapy in young adults to induce earlier "catch up" to peak bone mass, and then enzyme replacement in later adulthood to prevent decrements in bone mass related to Gaucher cell infiltration.

Original languageEnglish (US)
Pages (from-to)597-601
Number of pages5
JournalJournal of Bone and Mineral Metabolism
Volume22
Issue number6
DOIs
StatePublished - Nov 2004
Externally publishedYes

Fingerprint

Enzyme Therapy
Gaucher Disease
Bone Density
Osteoporosis
Enzymes
Lysosomal Storage Diseases
Enzyme Replacement Therapy
Therapeutics
Bone and Bones
Femur Neck
Photon Absorptiometry
Israel
Young Adult
Spine
Exercise

Keywords

  • Bone mineral density
  • DEXA
  • Enzyme replacement therapy
  • Gaucher disease
  • Osteoporosis

ASJC Scopus subject areas

  • Endocrinology

Cite this

Lebel, E., Dweck, A., Foldes, A. J., Golowa, Y. S., Itzchaki, M., Zimran, A., & Elstein, D. (2004). Bone density changes with enzyme therapy for Gaucher disease. Journal of Bone and Mineral Metabolism, 22(6), 597-601. https://doi.org/10.1007/s00774-004-0529-8

Bone density changes with enzyme therapy for Gaucher disease. / Lebel, Ehud; Dweck, Altoon; Foldes, A. Joseph; Golowa, Yosef S.; Itzchaki, Menachem; Zimran, Ari; Elstein, Deborah.

In: Journal of Bone and Mineral Metabolism, Vol. 22, No. 6, 11.2004, p. 597-601.

Research output: Contribution to journalArticle

Lebel, E, Dweck, A, Foldes, AJ, Golowa, YS, Itzchaki, M, Zimran, A & Elstein, D 2004, 'Bone density changes with enzyme therapy for Gaucher disease', Journal of Bone and Mineral Metabolism, vol. 22, no. 6, pp. 597-601. https://doi.org/10.1007/s00774-004-0529-8
Lebel, Ehud ; Dweck, Altoon ; Foldes, A. Joseph ; Golowa, Yosef S. ; Itzchaki, Menachem ; Zimran, Ari ; Elstein, Deborah. / Bone density changes with enzyme therapy for Gaucher disease. In: Journal of Bone and Mineral Metabolism. 2004 ; Vol. 22, No. 6. pp. 597-601.
@article{8eb403d0b0fc4d36a795d4c34161bfcb,
title = "Bone density changes with enzyme therapy for Gaucher disease",
abstract = "Gaucher disease is the most common lysosomal storage disease. Enzyme replacement therapy engenders improvement in hematological and visceral parameters; however, improvement in bone density (BMD) with treatment has not been confirmed. This study presents follow-up of BMD in the first tenpatients in Israel treated with low-dose recombinant enzyme for up to 108 months. BMD at femoral neck and lumbar spine was determined by dual-energy X-ray absorptiometry (DEXA) at the start of the trial, after 3-6 months, after 18-24 months, and at the most recent follow-up. BMD in all patients was very low at onset and never normalized. There was a decrease in BMD in all patients at 3-6 months. Older patients (four women, two men; >30 years of age) showed some improvement in BMD during treatment. Younger patients (four females; 18-23 years of age) did not show a statistically significant improvement. These findings might reflect the failure of patients with Gaucher disease to achieve expected peak bone density at appropriate chronological milestones despite treatment. None-theless, the z-scores of the older patients were better than those of the younger patients, implying some catch-up period. Yet, some patients with Gaucher disease evince rapid onset of osteoporosis in early adulthood. Enzyme treatment per se, as well as attendant improved well-being and increased physical activity, may induce amelioration in BMD at this later stage. One may consider adding anti-osteoporosis therapy in young adults to induce earlier {"}catch up{"} to peak bone mass, and then enzyme replacement in later adulthood to prevent decrements in bone mass related to Gaucher cell infiltration.",
keywords = "Bone mineral density, DEXA, Enzyme replacement therapy, Gaucher disease, Osteoporosis",
author = "Ehud Lebel and Altoon Dweck and Foldes, {A. Joseph} and Golowa, {Yosef S.} and Menachem Itzchaki and Ari Zimran and Deborah Elstein",
year = "2004",
month = "11",
doi = "10.1007/s00774-004-0529-8",
language = "English (US)",
volume = "22",
pages = "597--601",
journal = "Journal of Bone and Mineral Metabolism",
issn = "0914-8779",
publisher = "Springer Japan",
number = "6",

}

TY - JOUR

T1 - Bone density changes with enzyme therapy for Gaucher disease

AU - Lebel, Ehud

AU - Dweck, Altoon

AU - Foldes, A. Joseph

AU - Golowa, Yosef S.

AU - Itzchaki, Menachem

AU - Zimran, Ari

AU - Elstein, Deborah

PY - 2004/11

Y1 - 2004/11

N2 - Gaucher disease is the most common lysosomal storage disease. Enzyme replacement therapy engenders improvement in hematological and visceral parameters; however, improvement in bone density (BMD) with treatment has not been confirmed. This study presents follow-up of BMD in the first tenpatients in Israel treated with low-dose recombinant enzyme for up to 108 months. BMD at femoral neck and lumbar spine was determined by dual-energy X-ray absorptiometry (DEXA) at the start of the trial, after 3-6 months, after 18-24 months, and at the most recent follow-up. BMD in all patients was very low at onset and never normalized. There was a decrease in BMD in all patients at 3-6 months. Older patients (four women, two men; >30 years of age) showed some improvement in BMD during treatment. Younger patients (four females; 18-23 years of age) did not show a statistically significant improvement. These findings might reflect the failure of patients with Gaucher disease to achieve expected peak bone density at appropriate chronological milestones despite treatment. None-theless, the z-scores of the older patients were better than those of the younger patients, implying some catch-up period. Yet, some patients with Gaucher disease evince rapid onset of osteoporosis in early adulthood. Enzyme treatment per se, as well as attendant improved well-being and increased physical activity, may induce amelioration in BMD at this later stage. One may consider adding anti-osteoporosis therapy in young adults to induce earlier "catch up" to peak bone mass, and then enzyme replacement in later adulthood to prevent decrements in bone mass related to Gaucher cell infiltration.

AB - Gaucher disease is the most common lysosomal storage disease. Enzyme replacement therapy engenders improvement in hematological and visceral parameters; however, improvement in bone density (BMD) with treatment has not been confirmed. This study presents follow-up of BMD in the first tenpatients in Israel treated with low-dose recombinant enzyme for up to 108 months. BMD at femoral neck and lumbar spine was determined by dual-energy X-ray absorptiometry (DEXA) at the start of the trial, after 3-6 months, after 18-24 months, and at the most recent follow-up. BMD in all patients was very low at onset and never normalized. There was a decrease in BMD in all patients at 3-6 months. Older patients (four women, two men; >30 years of age) showed some improvement in BMD during treatment. Younger patients (four females; 18-23 years of age) did not show a statistically significant improvement. These findings might reflect the failure of patients with Gaucher disease to achieve expected peak bone density at appropriate chronological milestones despite treatment. None-theless, the z-scores of the older patients were better than those of the younger patients, implying some catch-up period. Yet, some patients with Gaucher disease evince rapid onset of osteoporosis in early adulthood. Enzyme treatment per se, as well as attendant improved well-being and increased physical activity, may induce amelioration in BMD at this later stage. One may consider adding anti-osteoporosis therapy in young adults to induce earlier "catch up" to peak bone mass, and then enzyme replacement in later adulthood to prevent decrements in bone mass related to Gaucher cell infiltration.

KW - Bone mineral density

KW - DEXA

KW - Enzyme replacement therapy

KW - Gaucher disease

KW - Osteoporosis

UR - http://www.scopus.com/inward/record.url?scp=8744297087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8744297087&partnerID=8YFLogxK

U2 - 10.1007/s00774-004-0529-8

DO - 10.1007/s00774-004-0529-8

M3 - Article

VL - 22

SP - 597

EP - 601

JO - Journal of Bone and Mineral Metabolism

JF - Journal of Bone and Mineral Metabolism

SN - 0914-8779

IS - 6

ER -